Immune Design
May 11, 2015

Immune Design to Present at Upcoming Investment Conferences

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at upcoming investor conferences in May and June.

Bank of America Merrill Lynch 2015 Health Care Conference
Thursday, May 14, 2015 at 9:20 a.m. Pacific Time in Las Vegas.
 
UBS 2015 Global Healthcare Conference
Tuesday, May 19, 2015 at 2 p.m. Eastern Time in New York.
 
Jefferies 2015 Healthcare Conference
Wednesday, June 3, 2015 at 2 p.m. Eastern Time in New York.

A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of each presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications

         julie@rathbuncomm.com

         206-769-9219



         Investor Contact

         Shari Annes

         Annes Associates

         sannes@annesassociates.com

         650-888-0902

company logo

Source: Immune Design

News Provided by Acquire Media